Release Date: October 21, 2016
Expiration Date: October 21, 2017

Expected time to complete this activity as designed: 120 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

The rapid pace of scientific advances in lymphoma research makes it challenging for clinicians to stay up-to-date on the latest treatment options and ongoing clinical trials. To meet this challenge, a panel of lymphoma experts has provided the latest information on current and future developments in the treatment of CD30+ lymphomas and on novel therapeutic options that target CD30 in HL. Summaries of recent clinical trials studying CD30-targeted therapy in other lymphoma subtypes will address safety and efficacy data in these diseases.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their knowledge of current and emerging treatments for CD30-positive lymphomas.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

• Recognize the clinical significance of CD30 as a biomarker in Hodgkin lymphoma and other malignant lymphomas
• Summarize the safety and efficacy data of novel agents and treatment strategies in Hodgkin lymphoma
• Outline the clinical trial data for emerging therapies in CD30-expressing lymphomas

Agenda

CD30 Expression in Hodgkin Lymphoma – Anton Hagenbeek, MD, PhD – Activity Chair
The Promising Role for Anti-CD30 Treatment in a Wider Subset of CD30+ Lymphomas – Tim Illidge, PhD, MRCP, FRCR, FRCPath
The Evolving Role of Targeted Therapy for Patients with CD30+ Hodgkin Lymphoma – Anas Younes, MD

Instructions for Participation and Credit

This activity is eligible for credit through October 21, 2017. After this date, this activity will expire and no further credit will be awarded.

1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Anton Hagenbeek, MD, PhD
Professor of Hematology
University Medical Center Utrecht
The Netherlands

Dr. Anton Hagenbeek received his medical degree from the Erasmus University in Rotterdam. He was trained in experimental hematology in the Radiobiological Institute T.N.O. in Rijswijk where he obtained his PhD and after training in internal medicine/hematology in Rotterdam, completed a fellowship in hematology at University of California, Los Angeles (UCLA). Dr. Hagenbeek is a Professor of Hematology at the University Medical Center Utrecht, The Netherlands, and holds a joint appointment as Professor of Hematology in the Department of Hematology, Academic Medical Center, University of Amsterdam, The Netherlands.

His main research interests began with developmental therapeutics for leukemia, focusing on translational research from preclinical animal models and in vitro studies to clinical application. From studies on minimal residual disease and experimental bone marrow transplantation (GVHD-GVL), Dr. Hagenbeek then moved into immuno-gene therapy of hematological malignancies. To date, his clinical research activities are mainly in the field of (intergroup) studies in non-Hodgkin's lymphomas and Hodgkin lymphomas. He has established two (international) consortia dealing with developing new biological prognostic indices in lymphoma and running first-in-man phase I/II studies with new agents in the lymphomas and chronic lymphocytic leukemia (CLL). Dr. Hagenbeek has authored/co-authored 335 papers in peer-reviewed journals.

Tim Illidge, PhD, MRCP, FRCR, FRCPath
Professor of Targeted Therapy and Oncology
Institute of Cancer Sciences
The University of Manchester
Manchester, United Kingdom

Dr. Tim Illidge completed his undergraduate degree in biochemistry (BSc) at London University, received his medical degree from Guy’s Hospital Medical School, London, and subsequently was awarded a PhD from the University of Southampton for his work in the field of antibody targeting in lymphoma. He completed research fellowships as CRUK senior clinical research fellow and was appointed senior lecturer and honorary consultant in oncology at Southampton University Hospitals NHS Trust. Dr. Illidge was awarded a US senior Fulbright fellowship and a Winston Churchill fellowship which enabled him to work as part of the lymphoma team at Stanford University, California. He later moved his research group to Manchester University based on the Christie Hospital site. Dr. Illidge is currently Professor of Targeted Therapy and Oncology at the Institute of Cancer Sciences, University of Manchester.

Dr. Illidge’s clinical interest is lymphoma where he has published extensively, including many early phase and late clinical trials focused on antibodies, antibody drug conjugates, radioimmunotherapy, and response-adjusted therapy in lymphoma.

Anas Younes, MD
Chief, Lymphoma Service
Division of Hematologic Oncology, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Dr. Anas Younes received his medical degree from the University of Damascus School of Medicine in Syria. He completed residencies in pathology at the Medical College of Ohio and in internal medicine at SUNY Downstate Medical Center, as well as a fellowship in hematology/oncology at Memorial Sloan Kettering Cancer Center. Dr. Younes is Chief of Memorial Sloan Kettering's Lymphoma Service, Division of Hematologic Oncology, where he is responsible for continuing to accelerate the translation of scientific discoveries into novel treatment strategies to improve the cure rate and survival of patients with Hodgkin and non-Hodgkin lymphoma.

Dr. Younes, a board-certified medical oncologist, serves on the Scientific Advisory Board of the Lymphoma Research Foundation, and is a past member of the National Cancer Institute Lymphoma Steering Committee. He has served as the principal investigator of more than 60 clinical trials and led the National Cancer Institute–funded SPORE (Specialized Programs of Research Excellence) in lymphoma.

Accreditation

	CME CREDIT Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
	CPE CREDIT MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 2.0 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-16-087-H01-P. Knowledge-based CPE activity. In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the login/registration on the home page of this site.
	NURSING CREDIT Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 2.0 contact hours. Program Number: 16-087-033

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Anton Hagenbeek has disclosed no relevant financial relationships.

Dr. Tim Illidge has received honoraria related to speakers’ bureau activities from F. Hoffmann-La Roche Ltd. and Takeda Oncology, and as a consultant from Nordic Nanovector. He has received grant support related to research activities from AstraZeneca, F. Hoffmann-La Roche, and MedImmune, LLC.

Dr. Anas Younes has received honoraria as a consultant from Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Incyte Corporation, Janssen Pharmaceuticals, Inc., Sanofi, Seattle Genetics, Inc., Merck & Co., Inc., and Takeda Oncology. He has received grant support related to research activities from Bristol-Myers Squibb, Curis, Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., and Novartis AG.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, and Patrick Brooks, PharmD, Medical Director, Oncology, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Physician Payments, Sunshine Act

MediCom Worldwide, Inc. complies with the Physician Payments Sunshine Act as part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfer of value provided to any covered recipient under the ACA.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer^® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows^® Vista, Windows^® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe^® Flash^® Player, Adobe^® Acrobat^®, Windows Media^® Player, and/or Microsoft^® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected].

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Takeda Oncology.

©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.